Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2022

Revenue From Contract With Customer [Abstract]

Schedule of Timing of Revenue Recognition

The following table illustrates the timing of the Company’s revenue recognition:

	Three Months Ended March 31,
	2022			2021
Software products and services – point in time		44.8	%		54.0	%
Software products and services – over time		23.2			28.0
Drug Discovery – point in time		19.0			-
Drug Discovery – over time		13.0			18.0

Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue

The following table presents the revenue recognized from the sources of software products and services revenue:

	Three Months Ended March 31,
	2022		2021
On-premise software	$	21,686	$	17,355
Hosted software		3,255		2,600
Software maintenance		4,726		4,105
Professional services		3,414		2,280
Total software revenue	$	33,081	$	26,340

Drug Discovery Revenue

The following table presents the revenue recognized from the sources of drug discovery revenue:

	Three Months Ended March 31,
	2022		2021
Drug discovery services revenue from contracts with customers	$	15,241	$	5,787
Drug discovery contribution		341		—
Total drug discovery revenue	$	15,582	$	5,787

Schedule of Contract Balances

Contract balances were as follows:

	As of March 31,		As of December 31,
	2022		2021
Contract assets	$	14,765	$	8,271
Deferred revenue, short-term:
Software products and services		32,074		32,945
Drug discovery		21,697		22,423
Deferred revenue, long-term:
Software products and services		3,633		3,938
Drug discovery		20,949		26,126